|
Following nine years in public accounting practice with Pricewaterhouse Coopers, Mr. Van Damme has spent 25 years as a senior financial executive of a number of U.S. and Canadian companies. Over the past ten years, he has primarily served as a CFO in the biotechnology industry and has experience with public companies including TSX and NYSE listed companies such as Allelix Biopharmaceuticals, Lorus Therapeutics, and Laidlaw Inc. His U.S. experience includes NASDAQ-listed NPS Pharmaceuticals, Inc. where he functioned as its Vice-President, Finance Canada after its acquisition and merger with Allelix. Mr. Van Damme is a Chartered Accountant and holds an MBA from the University of Toronto. | 